<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004705</url>
  </required_header>
  <id_info>
    <org_study_id>P-080647-01</org_study_id>
    <nct_id>NCT01004705</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol</brief_title>
  <official_title>Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Study of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin, and Ramipril in Subjects With Elevated LDL Cholesterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferrer Internacional S.A.</source>
  <brief_summary>
    <textblock>
      This study evaluates the effect on LDL cholesterol of the 3 drugs given together in the
      cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin, and ramipril)
      as compared to the effect on LDL cholesterol of simvastatin given alone. Approximately 76
      subjects will be screened, 60 randomized in order about 52 subjects to finish the study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Difference in LDL Cholesterol Levels Between the Basal and the Final Visit of Each Treatment Period.</measure>
    <time_frame>Day 1 and Day 84 of the Period 1 and Day 126 and Day 210 of Period 2</time_frame>
    <description>Change from baseline in LDL cholesterol level following each Treatment Period was defined as the difference between the measurements from the baseline visit (Visit 4, Day 1) and Visit 9 (Day 84) for Treatment Period 1, and between the Visit 11 (Day 126) and Visit 16 (Day 210) for Treatment Period 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Difference in Mean Total Cholesterol Between the Basal and the Final Visit of Each Treatment Period.</measure>
    <time_frame>Day 1 and Day 84 of the Period 1 and Day 126 and Day 210 of Period 2</time_frame>
    <description>Change from baseline in mean total cholesterol level following each Treatment Period was defined as the difference between the measurements from the baseline visit (Visit 4, Day 1) and Visit 9 (Day 84) for Treatment Period 1, and between the Visit 11 (Day 126) and Visit 16 (Day 210) for Treatment Period 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Elevated LDL Cholesterol</condition>
  <arm_group>
    <arm_group_label>Fixed Dose Combination Pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral dose of combination of acetylsalicylic acid, simvastatin, and ramipril (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 or 10 mg ramipril)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily oral dose of Simvastatin 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),</intervention_name>
    <description>A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.</description>
    <arm_group_label>Fixed Dose Combination Pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>A once daily oral dose of simvastatin for 12 weeks.</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥18 years of age

          -  Previously untreated LDL cholesterol ≥100 mg/dL and ≤180 mg/dL.

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Subjects with a medical condition requiring chronic pharmacological treatment

          -  On direct questioning and physical examination have evidence of any clinically
             significant chronic disease, including known or suspected human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

          -  On direct questioning and physical examination have a medical history or evidence of
             abuse of drugs.

          -  Medical history of gastrointestinal bleeding or gastric or duodenal ulcer.

          -  Systolic pressure ≥140 mmHg or diastolic pressure &gt;89 mmHg requiring hypotensive
             medication.

          -  Presence of secondary dyslipidemia.

          -  Previous use of cholesterol lowering medication.

          -  Previous coronary artery bypass graft (CABG).

          -  Previous percutaneous transluminal coronary angioplasty (PTCA) with a drug-eluting
             stent.

          -  Presence of severe congestive heart failure (New York Heart Classification [NYHC] III
             IV).

          -  Presence of untreated or uncontrolled thyroid disease.

          -  Past or current medical history of asthma or aspirin induced asthma

          -  Previous hypersensitivity to ACE inhibitors (eg angioedema or cough).

          -  Previous hypersensitivity to ARBs.

          -  History of unstable angina.

          -  Serum creatinine &gt;2 mg/dL.

          -  Creatine phosphokinase (CPK) ≥5 x the upper limit of normal (ULN).

          -  Hemoglobin ≤12 g/dL (120 g/L) for male subjects or ≤10 g/dL (100 g/L) for female
             subjects.

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 x ULN.

          -  Total bilirubin ≥1.5 x ULN.

          -  Serum triglyceride concentration ≥400 mg/dL.

          -  Subjects not using effective contraception methods (intra uterine device [IUD] and
             condom or diaphragm with spermicide and condom) during the study and for at least one
             month thereafter.

          -  Pregnant, lactating, breastfeeding, or intends to become pregnant during the course of
             the study (females only). All women must have a negative urine pregnancy test at the
             Screening Visit, be surgically sterile (bilateral tubal ligation, bilateral
             oophorectomy, or hysterectomy) or have a postmenopausal status (no menses) for at
             least one year.

          -  Contraindications to or known or suspected hypersensitivity to aspirin, simvastatin or
             ramipril or their excipients.

          -  Presence of mental illness limiting the capacity for self-care.

          -  Presence of major systemic illnesses: renal disease, liver disease, neurological or
             psychiatric disease.

          -  Participation, in the 30 days preceding enrolment into the study, in any other
             clinical study in which investigational or marketed drugs were employed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>NY 10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <results_first_submitted>June 1, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular</keyword>
  <keyword>fixed</keyword>
  <keyword>dose</keyword>
  <keyword>combination</keyword>
  <keyword>pill</keyword>
  <keyword>LDL</keyword>
  <keyword>cholesterol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>126 subjects were screened, 47 met eligibility requirements and 44 entered the run-in period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-randomization Run-In</title>
          <description>Screening period with ramipril 2.5 mg</description>
        </group>
        <group group_id="P2">
          <title>Combination Pill Then Simvastatin</title>
          <description>After randomization, in Period 1 participants received a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 11 weeks; participants received no intervention during wash-out; in Period 2 participants received a once daily oral dose of 40 mg simvastatin for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Simvastatin Then Combination Pill</title>
          <description>After randomization, in Period 1 participants received a once daily oral dose of 40 mg simvastatin for 12 weeks; participants received no intervention during wash-out; in Period 2 participants received a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 11 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-In</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1 (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Randomized Patients</title>
          <description>All patients randomized to both study sequences (Combination Pill then Simvastatin and Simvastatin then Combination Pill)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Difference in LDL Cholesterol Levels Between the Basal and the Final Visit of Each Treatment Period.</title>
        <description>Change from baseline in LDL cholesterol level following each Treatment Period was defined as the difference between the measurements from the baseline visit (Visit 4, Day 1) and Visit 9 (Day 84) for Treatment Period 1, and between the Visit 11 (Day 126) and Visit 16 (Day 210) for Treatment Period 2.</description>
        <time_frame>Day 1 and Day 84 of the Period 1 and Day 126 and Day 210 of Period 2</time_frame>
        <population>Per Protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Pill</title>
            <description>Once daily oral dose of combination pill containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>Once daily oral dose of 40 mg simvastatin for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference in LDL Cholesterol Levels Between the Basal and the Final Visit of Each Treatment Period.</title>
          <description>Change from baseline in LDL cholesterol level following each Treatment Period was defined as the difference between the measurements from the baseline visit (Visit 4, Day 1) and Visit 9 (Day 84) for Treatment Period 1, and between the Visit 11 (Day 126) and Visit 16 (Day 210) for Treatment Period 2.</description>
          <population>Per Protocol population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.24" spread="27.103"/>
                    <measurement group_id="O2" value="-27.95" spread="32.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Difference in Mean Total Cholesterol Between the Basal and the Final Visit of Each Treatment Period.</title>
        <description>Change from baseline in mean total cholesterol level following each Treatment Period was defined as the difference between the measurements from the baseline visit (Visit 4, Day 1) and Visit 9 (Day 84) for Treatment Period 1, and between the Visit 11 (Day 126) and Visit 16 (Day 210) for Treatment Period 2.</description>
        <time_frame>Day 1 and Day 84 of the Period 1 and Day 126 and Day 210 of Period 2</time_frame>
        <population>Per Protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Pill</title>
            <description>Once daily oral dose of combination pill containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril for 11 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin</title>
            <description>Once daily oral dose of 40 mg simvastatin for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference in Mean Total Cholesterol Between the Basal and the Final Visit of Each Treatment Period.</title>
          <description>Change from baseline in mean total cholesterol level following each Treatment Period was defined as the difference between the measurements from the baseline visit (Visit 4, Day 1) and Visit 9 (Day 84) for Treatment Period 1, and between the Visit 11 (Day 126) and Visit 16 (Day 210) for Treatment Period 2.</description>
          <population>Per Protocol population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.81" spread="28.715"/>
                    <measurement group_id="O2" value="-29.81" spread="38.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pre-randomization Run-In</title>
          <description>Screening period with ramipril 2.5 mg</description>
        </group>
        <group group_id="E2">
          <title>Combination Pill</title>
          <description>Combination pill containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril for 11 weeks</description>
        </group>
        <group group_id="E3">
          <title>Simvastatin</title>
          <description>Once daily oral dose of 40 mg simvastatin for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood phosphokinase creatine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication must be agreed upon with the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Natalia Oudovenko</name_or_title>
      <organization>Ferrer Internacional S.A.</organization>
      <phone>+34 93 509 32 82</phone>
      <email>noudovenko-research@ferrergrupo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

